K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 31.85 HKD -2.3%
Market Cap: 8.9B HKD
Have any thoughts about
KeyMed Biosciences Inc?
Write Note

KeyMed Biosciences Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

KeyMed Biosciences Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
K
KeyMed Biosciences Inc
HKEX:2162
Accounts Payable
ÂĄ29.5m
CAGR 3-Years
105%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accounts Payable
ÂĄ3.7B
CAGR 3-Years
20%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Accounts Payable
ÂĄ220.6m
CAGR 3-Years
-7%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accounts Payable
ÂĄ299.9m
CAGR 3-Years
39%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accounts Payable
ÂĄ16.3B
CAGR 3-Years
23%
CAGR 5-Years
42%
CAGR 10-Years
91%
Imeik Technology Development Co Ltd
SZSE:300896
Accounts Payable
ÂĄ44.7m
CAGR 3-Years
113%
CAGR 5-Years
17%
CAGR 10-Years
N/A
No Stocks Found

KeyMed Biosciences Inc
Glance View

Market Cap
8.9B HKD
Industry
Biotechnology

In the bustling city of Chengdu, China, amid the rise of modern medical innovation, KeyMed Biosciences Inc. has emerged as a prominent player in the biotechnology sector. Established by a team of experienced scientists and industry veterans, the company focuses on the discovery and development of novel biologic therapies aimed at addressing critical unmet medical needs, particularly within the oncology and autoimmune disease spaces. With its proprietary technology platforms, KeyMed drives its research and development by leveraging extensive capabilities in monoclonal antibody discovery and engineering. This approach allows the company to create innovative products that potentially offer superior efficacy and safety profiles compared to existing treatments, thus underpinning its mission to contribute significantly to global healthcare advancements. KeyMed Biosciences operates on a business model primarily centered around product development pipelines, strategic partnerships, and licensing agreements. The company's revenue streams are chiefly generated from licensing out its proprietary drug candidates and technologies to major pharmaceutical companies, who seek late-stage and commercialized assets. These collaborations not only provide the financial means necessary to fuel ongoing R&D but also facilitate accelerated development timelines and expand the reach of their therapeutic innovations. Furthermore, as these candidates progress through clinical trials and receive regulatory approvals, KeyMed stands to gain from milestone payments and, eventually, a share of sales revenues. This symbiotic relationship between cutting-edge research and astute financial strategies defines KeyMed's path forward in a competitive industry landscape.

Intrinsic Value
17.51 HKD
Overvaluation 45%
Intrinsic Value
Price
K

See Also

What is KeyMed Biosciences Inc's Accounts Payable?
Accounts Payable
29.5m CNY

Based on the financial report for Dec 31, 2023, KeyMed Biosciences Inc's Accounts Payable amounts to 29.5m CNY.

What is KeyMed Biosciences Inc's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
105%

Over the last year, the Accounts Payable growth was 98%. The average annual Accounts Payable growth rates for KeyMed Biosciences Inc have been 105% over the past three years .

Back to Top